• 1
    Reddy S, Bruera E, Pace E, Zhang K, Reyes-Gibby CC. Clinically important improvement in the intensity of fatigue in patients with advanced cancer. J Palliat Med. 2007; 10: 1068-1075.
  • 2
    Forlenza M, Hall P, Lichtenstein P, Evengard B, Sullivan PF. Epidemiology of cancer-related fatigue in the Swedish twin registry. Cancer. 2005; 104: 2022-2031.
  • 3
    Wagner L, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer. 2004; 91: 822-828.
  • 4
    Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet. 2003; 362: 640-650.
  • 5
    Stone P, Richards M, A'Hern R, Hardy J. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol. 2000; 11: 561-567.
  • 6
    Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double blind placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with HIV disease. Arch Intern Med. 2001; 161: 411-420.
  • 7
    Smets E, Garssen B, Schuster-Ultterhoeve ALJ, de Haes JCJM. Fatigue in cancer patients. Br J Cancer. 1993; 68: 220-224.
  • 8
    Stone P, Hardy J, Huddart R, A'Hern R, Richards M. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer. 2000; 36: 1134-1141.
  • 9
    Barnes E, Bruera E. Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer. 2002; 12: 424-428.
  • 10
    Butt Z, Rosenbloom SK, Abernethy AP, et al. Fatigue is the most important symptom for advanced cancer patients who have chemotherapy. J Natl Compr Canc Netw. 2008; 6: 448-455.
  • 11
    American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society; 2008.
  • 12
    Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol. 2006; 176( pt 1): 2443-2447.
  • 13
    Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK. Response to low-dose ketoconazole and subsequent dose escalation to high-doe ketoconazole in patients with androgen-independent prostate cancer. Cancer. 206; 107: 975-981.
  • 14
    Bok R, Small EJ. The treatment of advanced prostate cancer with ketoconazole: safety issues. Drug Saf. 1999; 20: 451-458.
  • 15
    Kunkel E, Bakker JMR, Myers RE, Oyesanmi O, Gomella LG. Biopsychosocial aspects of prostate cancer. Psychosomatics. 2000; 41: 85-94.
  • 16
    Zelefsky M, Kelly WK, Scher HI, et al. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose 3-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. J Clin Oncol. 2000; 18: 1936-1941.
  • 17
    Monga U, Kerrigan AJ, Thornby J, Monga TN. Prospective study of fatigue in localized prostate cancer patients undergoing radiotherapy. Radiat Oncol Investig. 1999; 7: 178-185.
  • 18
    Bruera E, Chadwick S, Brennels C, Hanson J, MacDonald RN. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treatment Rep. 1987; 71: 67-70.
  • 19
    Breitbart W, Mermelstein C. An alternative psychostimulant for the management of depressive disorders in cancer patients. Psychosomatics. 1992; 33: 353-356.
  • 20
    Sarhill N, Walsh D, Nelson KA, Homsi J, LeGrand S, Davis MP. Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study. Am J Hosp Palliat Care. 2001; 18: 187-192.
  • 21
    Iop A, Manfredi AM, Bonura S. Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Ann Oncol. 2004; 15: 712-720.
  • 22
    Kornblith A, Herr HW, Ofman US, Scher HI, Holland JC. Quality of life of patients with prostate cancer and their spouses: the value of a database in clinical care. Cancer. 1994; 73: 2791-2802.
  • 23
    Portenoy R. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994; 30A: 1326-1336.
  • 24
    Katon W, Raskind M. Treatment of depression in the medically ill elderly with methylphenidate. Am J Psychiatry. 1980; 137: 963-965.
  • 25
    Kaufmann M, Murray GB, Cassem NH. Use of psychostimulants in medically ill depressed patients. Psychosomatics. 1982; 23: 817-819.
  • 26
    Fernandez F, Levy J, Galizzi H. Response of HIV-related depression to psychostimulants: case reports. Hosp Community Psychiatry. 1988; 39: 628-631.
  • 27
    Holmes V, Fernandez F, Levy JK. Psychostimulant response in AIDS-related complex patients. J Clin Psychiatry. 1989; 50: 5-8.
  • 28
    Bruera E, El Osta B, Valero V, et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2007; 25: 475-481.
  • 29
    Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2006; 24: 2073-2078.
  • 30
    Sood A, Barton DL, Loprinzi CL. Use of methylphenidate in patients with cancer. Am J Hosp Palliat Care. 2006; 23: 35-40.
  • 31
    Lower E, Fleishman S, Cooper A, Zeldis J, Faleck H, Manning D. A phase III, randomized placebo-controlled trial of the safety and efficacy of d-MPH as new treatment of fatigue and “chemobrain” in adult cancer patients. J Clin Oncol. 2005; 23( 16 suppl): 8000.
  • 32
    Mock V. Evidence-based treatment for cancer-related fatigue. J Natl Cancer Inst Monogr. 2004;( 32): 112-118.
  • 33
    Cullum J, Wojciechowski AE, Pelletier G, Simpson JS. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry. 2004; 49: 139-144.
  • 34
    Bruera E, Brenneis C, Paterson AH, MacDonald RN. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage. 1989; 4: 3-6.
  • 35
    Schmitz K, Holtzman J, Courneya KS, Masse LC, Duval S, Kane R. Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1588-1595.
  • 36
    Monga U, Garber SL, Thornby J, et al. Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. Arch Phys Med Rehabil. 2007; 88: 1416-1422.
  • 37
    Atkinson A, Barsevick A, Cella D, et al. NCCN practice guidelines for cancer-related fatigue. Oncology. 2000; 14: 151-161.
  • 38
    Bruera E, MacDonald RN. Asthenia in patients with advanced cancer. J Pain Symptom Manage. 1988; 3: 9-14.
  • 39
    Segal R, Reid RD, Courneya KS, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol. 2009; 27: 344-351.
  • 40
    Culos-Reed S, Robinson JL, Lau H, O'Connor K, Keats MR. Benefits of a physical activity intervention for men with prostate cancer. J Sport Exerc Psychol. 2007; 29: 118-127.
  • 41
    Windsor P, Nicol KF, Potter J. A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer. 2004; 101: 550-557.
  • 42
    Segal R, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003; 21: 1653-1659.
  • 43
    Lower EE, Fleishman S, Cooper A, et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage. 2009; 38: 650-662.
  • 44
    Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999; 85: 1186-1196.
  • 45
    Krupp LB LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989; 46: 1121-1123.
  • 46
    Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67: 361-370.
  • 47
    Beck AT. Psychiatry: cognitive therapy for depression and panic disorder. West J Med. 1989; 151: 311.
  • 48
    Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570-579.
  • 49
    Rabkin JG, Markowitz JS, Ocepek-Welikson K, Wager SS. General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. J Clin Psychopharmacol. 1992; 12: 3-10.
  • 50
    Chouinard G, Chouinard AR, Aunable L, Jones BD. Extrapyramidal symptoms rating scale. Can J Neurol Sci. 1980; 3: 233-238.
  • 51
    Gadbury GL, Coffey CS, Allison DB. Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF. Obes Rev. 2003; 4: 175-184.
  • 52
    Mallinckrodt CH, Clark SW, Carroll RJ, Molenbergh G. Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat. 2003; 13: 179-190.
  • 53
    Babyak MA. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med. 2004; 66: 411-421.
  • 54
    MacCallum RC, Zhang S, Preacher KJ, Rucker DD. On the practice of dichotomization of quantitative variables. Psychol Methods. 2002; 7: 19-40.
  • 55
    Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006; 25: 127-141.
  • 56
    Guyatt G, Osaba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clinic Proc. 2002; 77: 371-383.
  • 57
    Gross D, Fogg L. A critical analysis of the intend-to-treat principle in prevention research. J Primary Prev. 2004; 25: 475-489.
  • 58
    Blackhall L, Petroni G, Shu J, Baum L, Farace E. A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. J Palliat Med. 2009; 12: 433-439.
  • 59
    Townsley C, Selby R, Siu LL. Systematic barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005; 23: 3112-3124.